Can you get retatrutide in the EU?

The short answer

Retatrutide is not available in the EU — it's still an investigational drug in phase 3 trials, with no EMA approval and no brand on the market anywhere as of 2026. That means there is no legal way to obtain it in the EU; any "retatrutide" sold online is gray-market and unverifiable. The realistic options are a clinical trial, or one of the approved GLP-1s while you wait.

Evidence tier: 2 — based on regulatory status (no EMA authorization) and published phase 2 data. Trial-timeline and access notes are practical and change as the program progresses. This is education, not medical or legal advice.

The key points:

• Not approved anywhere — retatrutide is still in phase 3 trials, no EMA marketing authorization
• No legal EU route — it isn't a prescription product yet
• Gray-market "retatrutide" is unverifiable — unapproved, unregulated, high risk
• Realistic options — a clinical trial, or an approved GLP-1 (semaglutide, tirzepatide) for now

This is part of our EU availability cluster — see the EU peptide availability overview and the full retatrutide deep dive.

Why isn't retatrutide available in the EU yet?

Evidence tier: 2 — regulatory status.

Retatrutide is an investigational triple-hormone-receptor agonist (GLP-1 + GIP + glucagon) still working through its late-stage clinical program — the phase 3 TRIUMPH trials — and it has not received marketing authorization from the EMA, the FDA, or any other major regulator. A drug can only be prescribed and dispensed once a regulator has reviewed its full safety and efficacy dossier and granted approval; until that happens, retatrutide simply isn't a product a doctor can write a prescription for or a pharmacy can stock, anywhere in the EU.

This is the crucial distinction from semaglutide and tirzepatide, which are EMA-approved and obtainable by prescription (see our semaglutide and tirzepatide EU guides). Retatrutide's strong early data — up to roughly 24% average weight loss at 48 weeks in its phase 2 trial (Jastreboff 2023) — is exactly why it's so discussed, but impressive trial results are not the same as an available medicine. Approval, if the phase 3 program succeeds, would still be some way off, and the EU timeline typically follows the dossier review process after trials complete.

Is there any legal way to get it in the EU?

Evidence tier: 2–3 — based on how investigational drugs are accessed.

For most people, no — not as a prescription. The one legitimate route to investigational drugs is enrolling in a clinical trial: the TRIUMPH program and related studies recruit participants in various countries, and trial participation is the only sanctioned way to receive retatrutide under medical supervision. Eligibility is restricted and trial sites are limited, so this isn't an option for everyone, but it's the only one that is both legal and safe. In rare cases, regulators operate compassionate-use or early-access schemes for serious unmet needs, but these are not a general route for an obesity drug still in trials.

What is emphatically not a safe or reliable route is buying "retatrutide" from online research-chemical vendors. Because the genuine drug isn't on the market, anything sold as retatrutide is unapproved, unregulated, and impossible to verify — you cannot know it's actually retatrutide, at the stated dose, free of contaminants. Injecting an unknown compound of this kind carries the purity and contamination risks detailed in our independent lab-testing guide, with the added problem that there's no reference standard to even test it against confidently.

What should you do if you want retatrutide now?

Evidence tier: 2–3 — practical synthesis.

If retatrutide specifically is the goal, the honest options are limited and worth being clear-eyed about. You can look into whether a TRIUMPH-program trial is recruiting near you — that's the only legitimate way to access the actual drug today. Or you can recognize that the available GLP-1s already deliver excellent results: tirzepatide reaches around 20%+ average weight loss and is approved and obtainable in the EU now, and semaglutide adds proven cardiovascular outcomes. For most people, an approved GLP-1 through a prescriber is a far better choice than waiting for — or worse, gray-market sourcing — an unapproved one.

The broader point for EU readers is that retatrutide is the clearest case in the whole availability spectrum: not a "hard to get" approved drug like the others, but a genuinely not yet available one. Treating early trial hype as a reason to chase an unverifiable online product trades a manageable wait for a real safety hazard. The patient move is to use what's approved now and watch the phase 3 readouts and the eventual EMA decision. The drug's mechanism and the data behind the excitement are covered in the retatrutide deep dive and our GLP-1 complete guide.

Why is the gray-market risk worse for retatrutide specifically?

Evidence tier: 2–3 — risk reasoning specific to an unapproved drug.

It's worth dwelling on why "research retatrutide" is a sharper hazard than gray-market versions of approved drugs. With semaglutide or tirzepatide, a counterfeit at least has a genuine, well-characterized reference product to be measured against — independent labs know exactly what real semaglutide should look like. Retatrutide has no marketed reference standard at all, because the genuine drug has never been sold. That makes anything labelled "retatrutide" doubly unverifiable: you can't confirm identity, purity, or dose against an established benchmark, and you're relying entirely on an unregulated seller's claim about a molecule that isn't commercially produced.

Layer on the usual injectable risks — heavy-metal and endotoxin contamination, mis-dosing, sterility — covered in our independent lab-testing guide, and the picture is that buying online "retatrutide" combines maximum uncertainty with the maximum-consequence delivery route. It's also a triple-agonist with a more complex pharmacology (including glucagon-receptor activity that can affect heart rate and other parameters), so getting an unknown dose of an unknown product is not a small gamble. The asymmetry is stark: the potential upside is "maybe it's real," and the downside is injecting an uncharacterized substance. For a drug whose approved cousins already work well and are obtainable, that trade makes little sense.

When might retatrutide actually be approved in the EU?

Evidence tier: 3 — informed expectation, not a guarantee.

No firm public date exists, and any estimate should be held loosely. The sequence is: the phase 3 TRIUMPH trials must complete and report, the manufacturer submits a dossier to the EMA, the EMA's committee reviews it, and only then can authorization follow. Each stage takes time, and approval is never guaranteed — drugs can stumble in phase 3 or in review. So while retatrutide is widely expected to reach the market given its phase 2 performance, "expected" is doing real work in that sentence, and the EU launch would typically trail the first approval elsewhere.

The practical takeaway is to treat any specific "retatrutide is coming in [year]" claim with skepticism, follow the trial readouts as they publish, and not make health decisions today on the assumption of a drug that isn't approved yet. Meanwhile the approved alternatives are real, and our EU guides for semaglutide and tirzepatide cover what you can actually get.

It's also worth setting expectations about what approval would and wouldn't change. Even after a hypothetical EU authorization, retatrutide would arrive as a prescription-only medicine with the same access realities as the rest of the class — eligibility criteria, national reimbursement decisions, and likely early supply constraints given the demand its data has already generated. In other words, "approved" would mean "obtainable through a prescriber, subject to cost and stock," not "freely available." So the gap between today's investigational status and a future where it's a practical option for most EU patients is larger than a single approval headline implies. That's another reason the steady move is to engage with the approved GLP-1s now and treat retatrutide as a promising future entrant rather than something to pursue prematurely through unsafe channels.

Limitations

This is educational content, not medical or legal advice.

• Retatrutide is investigational — not approved by the EMA or any major regulator as of 2026.
• Approval timelines are uncertain — phase 3 success and review timing are not guaranteed.
• Clinical-trial access is restricted — eligibility and sites are limited.
• Gray-market "retatrutide" is unverifiable and unsafe — there's no legitimate purchase route.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Retatrutide is not available in the EU — it remains an investigational phase 3 drug with no EMA approval and no marketed brand, so there's no legal prescription route. The only sanctioned way to receive it is a clinical trial; anything sold online as retatrutide is gray-market and unverifiable. Given that approved GLP-1s like tirzepatide and semaglutide already deliver excellent, regulated results in the EU today, the sensible path is to use what's approved and watch the phase 3 readouts rather than chase an unavailable drug.

Related on this site

• EU peptide availability: the overview
• Retatrutide deep dive (2026)
• Semaglutide in the EU (Ozempic, Wegovy, Rybelsus)
• Tirzepatide in the EU (Mounjaro)
• GLP-1 complete guide (2026)
• Retatrutide peptide page
• Our evidence-tier framework

References

• Jastreboff AM, Kaplan LM, Frías JP, et al. 2023. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 389(6):514-526. PMID 37366315 — phase 2 efficacy (~24% at top dose, 48 wk).
• Jastreboff AM, et al. 2023. Triple-hormone-receptor agonist retatrutide for obesity. PMID 37888926 — additional published retatrutide data.
• European Medicines Agency. EU actions to tackle shortages of GLP-1 receptor agonists. EMA news — context on the approved-GLP-1 alternatives and EU access.